Key clinical point: The universal chimeric antigen receptor T-cell therapy TruUCAR GC027 has produced responses in adults with relapsed/refractory T-cell acute lymphoblastic leukemia.
Major finding: Initally, 100% of patients achieved complete remission (CR) or CR with incomplete count recovery. At 1 month, 80% of patients had a CR and were minimal residual disease negative.
Study details: A phase 1 study of 5 patients.
Disclosures: Dr. Wang is an employee of Gracell Biotechnologies, the company developing TruUCAR GC027.
Wang X et al. AACR 2020, Abstract CT052.